# A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Study · id `cardio:ct-nct06292013` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06292013](<https://clinicaltrials.gov/study/NCT06292013>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06292013

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 17300 participants.

## Technical summary

Registry record NCT06292013. Randomized; double masking; primary purpose treatment. Start 2024-03-05 (actual); primary completion 2029-03 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 17300 participants (planned count; ClinicalTrials.gov record NCT06292013, source copy `cardio:ctgov-nct06292013-2026-10-08`, retrieved 2026-10-31)
- Started: 2024-03-05 (actual) (ClinicalTrials.gov record NCT06292013, source copy `cardio:ctgov-nct06292013-2026-10-08`, retrieved 2026-10-31)
- Primary completion: 2029-03 (anticipated) (ClinicalTrials.gov record NCT06292013, source copy `cardio:ctgov-nct06292013-2026-10-08`, retrieved 2026-10-31)
- Completion: 2029-03 (anticipated) (ClinicalTrials.gov record NCT06292013, source copy `cardio:ctgov-nct06292013-2026-10-08`, retrieved 2026-10-31)
- Countries: United States; Argentina; Australia; Austria; Belgium; Brazil; Canada; China; Czechia; Denmark; France; Germany; Greece; Hungary; India; Israel; Italy; Japan; Mexico; Netherlands; Poland; Puerto Rico; Romania; Slovakia; South Korea; Spain; Taiwan; United Kingdom (ClinicalTrials.gov record NCT06292013, source copy `cardio:ctgov-nct06292013-2026-10-08`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06292013-2026-10-08`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
- Condition: Atherosclerotic Cardiovascular Disease (ASCVD)
- Condition: Elevated Lp(a)
- Intervention (Drug): Lepodisiran Sodium
- Intervention (Drug): Placebo
- Lead sponsor: Eli Lilly and Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry lists this organization as the lead sponsor: Eli Lilly and Company (`cardio:eli-lilly`)

## Provenance

Content hash: 0d3ebb4d791d4016a9eae3bb3f77d564eb28e62d6aed1f17c9374ec3c2d8286a
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
